Sino Biopharmaceutical Limited

One of the main topics of conversation at the beginning of 2025 is how pharma companies should build their pipelines and the rising role that China is playing. A widely-cited report from Stifel show

AstraZeneca ended last year as the world’s seventh largest pharma company by market cap – but as the leading group when it comes to starting clinical trials. Last year AstraZeneca kicked off 139 tri

Innovent Biologics, Inc. and GenFleet Therapeutics on 21 August scored China’s first approval for a KRAS G12C inhibitor, the co-developed Dupert (fulzerasib), winning a head start over foreign and

As pharma firms in China feel they can’t get enough of the reimbursement coverage for innovative drugs provided by the National Basic Medical Insurance Fund, the country’s single public payer, one que